Urovant Sciences, Inc.: Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA (vibegron) 75 mg for Overactive Bladder at the 2021 Annual Meeting of the American Urological Association
Data from the dedicated, stand-alone, ambulatory blood pressure trial will be the focus of a podium presentation Efficacy in patients with 'dry' overactive bladder, based on a post-hoc analysis
Source: finanznachrichten.de